论文部分内容阅读
目的:评价喘可治注射液治疗急性发作期支气管哮喘效果与安全性。方法:2014年7月~2015年11月,观察组与对照组各纳入患者40例,均给予常规西医治疗,观察组联合喘可治注射液治疗。结果:观察组喘息、胸闷缓解时间低于对照组,差异具有统计学意义(P<0.05);治疗后,观察组与对照组症状评分、诱导痰嗜酸粒细胞水平低于治疗前,观察组低于对照组,两组PEF水平高于治疗前,观察组高于对照组,差异具有统计学意义(P<0.05);8周内,观察组复发或加重率低于对照组,差异具有统计学意义(P<0.05)。两组均未见不良反应。结论:喘可治注射液治疗急性发作期支气管哮喘效果较好,可加速增长缓解,预防复发。
Objective: To evaluate the efficacy and safety of Chuankezhi injection in the treatment of acute exacerbation of bronchial asthma. Methods: From July 2014 to November 2015, 40 patients in observation group and control group were enrolled in this study. All patients were given conventional western medicine. The observation group was treated with Chuankezhi injection. Results: The relief time of wheezing and chest tightness in the observation group was lower than that in the control group (P <0.05). After treatment, symptom scores and induced sputum eosinophils in the observation group and the control group were lower than those in the observation group The levels of PEF in the two groups were higher than those in the control group before the treatment, and the difference was statistically significant (P <0.05). Within 8 weeks, the recurrence or worsening rate of the observation group was lower than that of the control group Significance (P <0.05). No adverse reactions were seen in both groups. Conclusion: Chuankezhi injection is effective in treating bronchial asthma in acute exacerbation, which can accelerate the growth and relieve the recurrence.